Korean Journal of Internal Medicine最新文献_第8页

Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study. 单剂量伊夫洛单抗注射液对早期急性心肌梗死的疗效：一项回顾性单中心研究。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.3904/kjim.2024.080

Yongcheol Kim, Ji Woong Roh, Oh-Hyun Lee, Seok-Jae Heo, Eui Im, Deok-Kyu Cho, Byeong-Keuk Kim

{"title":"Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study.","authors":"Yongcheol Kim, Ji Woong Roh, Oh-Hyun Lee, Seok-Jae Heo, Eui Im, Deok-Kyu Cho, Byeong-Keuk Kim","doi":"10.3904/kjim.2024.080","DOIUrl":"10.3904/kjim.2024.080","url":null,"abstract":"Background/aims: Achieving rapid reduction of low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL in patients with acute myocardial infarction (AMI) can be challenging with statins alone. This single-center, retrospective study aimed to assess the impact of single-dose injection of evolocumab 140 mg on LDL-C levels during the peri-percutaneous coronary intervention (PCI) period in patients with AMI.Methods: A total of 95 patients with AMI who underwent PCI were divided into the evolocumab (n = 50) and non-evolocumab (n = 45) groups.Results: The percentage change of LDL-C level at 1-3 weeks from baseline was 78.4 ± 13.4% reduction in the evolocumab group versus 45.6 ± 22.6% in the non-evolocumab group, with a mean difference of -33.5% between the groups (95% CI: -42.6 to -24.5%; p < 0.001). The achievement rate of LDL-C levels below 55 mg/dL at 1-3 weeks was significantly higher in the evolocumab group than in the non-evolocumab group (97.7% vs. 60.0%, p < 0.001).Conclusion: Patients with AMI who received single-dose injection of evolocumab 140 mg during the peri-PCI period had a significantly greater LDL-C reduction and higher proportion of patients achieved the target LDL-C level in the early phase AMI than those who did not receive evolocumab.","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"793-800"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and chronic kidney disease, an important piece in the puzzle of Cardiovascular-Kidney- Metabolic syndrome. 肥胖症和慢性肾脏病是心血管-儿童-代谢综合征的重要组成部分。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.3904/kjim.2024.273

Young Youl Hyun

引用次数: 0

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis. 韩国血清反应阳性类风湿关节炎患者服用生物制剂和靶向合成改善病情抗风湿药物的药物保留率。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.3904/kjim.2023.297

Bong-Woo Lee, Jennifer Jooha Lee, Wan-Uk Kim

{"title":"Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis.","authors":"Bong-Woo Lee, Jennifer Jooha Lee, Wan-Uk Kim","doi":"10.3904/kjim.2023.297","DOIUrl":"10.3904/kjim.2023.297","url":null,"abstract":"Background/aims: The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis.Methods: This study was conducted with 1,538 treatment courses of 1,063 patients, including adalimumab (n = 332), etanercept (n = 369), infliximab (n = 146), abatacept (n = 152), tocilizumab (n = 299), tofacitinib (n = 136), and baricitinib (n = 104), in patients with seropositive rheumatoid arthritis who started b/tsDMARD treatment between 2008 and 2020 at Seoul St. Mary's Hospital. Discontinuation 1 and 3 years after the first prescription of each drug was investigated. Kaplan- Meier estimates of time to discontinuation were calculated to compare the difference in drug retention rate for each drug. Patient-level predictors of drug discontinuation were evaluated using a Cox proportional hazards model.Results: The overall 1-year drug retention rate was from 60.1% for adalimumab to 90.0% for tofacitinib in the b/tsDMARD-naïve group, and from 55.2% for infliximab to 84.8% for tofacitinib in the b/tsDMARD-experienced group. The 3-year drug retention rate was from 36.9% for infliximab to 86.5% for tofacitinib in the b/tsDMARD-naïve group, and from 31.0% for infliximab to 65.4% for tocilizumab in the b/tsDMARD-experienced group. Drug discontinuation appeared to be affected by specific types of b/tsDMARDs.Conclusion: Tocilizumab and tofacitinib are less commonly discontinued compared to tumor necrosis factor-α inhibitors at 1 and 3 years. Specifically, tofacitinib in the b/tsDMARD-naïve group and tocilizumab in the b/tsDMARD-experienced group showed the highest 3-year retention rates.","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"833-844"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity is associated with incident chronic kidney disease in individuals with normal renal function. 对于肾功能正常的人来说，肥胖与慢性肾病的发生有关。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.3904/kjim.2023.491

Su Hyun Song, Tae Ryom Oh, Sang Heon Suh, Hong Sang Choi, Chang Seong Kim, Seong Kwon Ma, Soo Wan Kim, Eun Hui Bae

{"title":"Obesity is associated with incident chronic kidney disease in individuals with normal renal function.","authors":"Su Hyun Song, Tae Ryom Oh, Sang Heon Suh, Hong Sang Choi, Chang Seong Kim, Seong Kwon Ma, Soo Wan Kim, Eun Hui Bae","doi":"10.3904/kjim.2023.491","DOIUrl":"10.3904/kjim.2023.491","url":null,"abstract":"Background/aims: Obesity has known to be a modifiable risk factor associated with worse outcomes in chronic kidney disease (CKD), but few studies have examined the impact of obesity on CKD incidence in the general population. The purpose of this study was to investigate the role of body mass index (BMI) and waist-to-hip ratio (WHR) as predictors of incident CKD and to evaluate the impact of weight reduction on CKD prevention.Methods: A total of 2,711 participants from a community-based cohort with normal renal function were prospectively analyzed. Among participants with obesity, we analyzed the change in WHR to evaluate the association of obesity reduction with CKD development.Results: During a mean follow-up of 11.03 ± 4.22 years, incident CKD occurred in 190 (7.0%) participants. In the fully adjusted multivariable Cox proportional hazard models, the risk of incident CKD increased with higher BMI (hazard ratio, 1.06; 95% confidence interval, 1.00-1.11; p = 0.033) and higher WHR (hazard ratio, 1.33; 95% confidence interval, 1.07-1.66; p = 0.009). In the Kaplan-Meier analysis, cumulative adverse renal events were significantly more common in the maintained obesity group than in the reduced obesity group (p = 0.001).Conclusion: Both higher BMI and WHR were associated with development of CKD, but the magnitude of the effect of WHR was higher than that of BMI. Moreover, reducing obesity would be beneficial for renal prognosis.","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"813-822"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seeking acceptance: how education shifts views on fecal microbiota transplants for ulcerative colitis in Korea. 寻求接受：教育如何转变韩国人对粪便微生物群移植治疗溃疡性结肠炎的看法。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.3904/kjim.2024.272

Jeongkuk Seo, Chang Hwan Choi

引用次数: 0

Acute pancreatitis by huge gastric phytobezoar. 巨大的胃植物虫引起急性胰腺炎。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.3904/kjim.2024.056

Dong-Ge Han, Yi-Xue Zhou, Wei Liu

引用次数: 0

Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study. 韩国溃疡性结肠炎患者对粪便微生物群移植的看法：KASID 多中心研究。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.3904/kjim.2024.053

Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon

{"title":"Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study.","authors":"Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon","doi":"10.3904/kjim.2024.053","DOIUrl":"https://doi.org/10.3904/kjim.2024.053","url":null,"abstract":"Background/aims: Fecal microbiota transplantation (FMT) is a promising therapy for inducing and maintaining remission in patients with ulcerative colitis (UC). However, FMT has not been approved for UC treatment in Korea. Our study aimed to investigate patient perceptions of FMT under the national medical policy.Methods: This was a prospective, multicenter study. Patients with UC ≥ 19 years of age were included. Patients were surveyed using 22 questions on FMT. Changes in perceptions of FMT before and after education were also compared.Results: A total of 210 patients with UC were enrolled. We found that 51.4% of the patients were unaware that FMT was an alternative treatment option for UC. After reading the educational materials on FMT, more patients were willing to undergo this procedure (27.1% vs. 46.7%; p < 0.001). The preferred fecal donor was the one recommended by a physician (41.0%), and the preferred transplantation method was the oral capsule (30.4%). A large proportion of patients (50.0%) reported that the national medical policy influenced their choice of FMT treatment. When patients felt severe disease activity, their willingness to undergo FMT increased (92.3% vs. 43.1%; p = 0.001).Conclusion: Education can increase preference for FMT in patients with UC. When patients have severe disease symptoms or their quality of life decreases their willingness to undergo FMT increases. Moreover, national medical policies may influence patient choices regarding FMT.","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"39 5","pages":"783-792"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current evidence for prognostic benefit of intravascular imaging-guided percutaneous coronary intervention in chronic total occlusion intervention. 血管内成像引导经皮冠状动脉介入治疗慢性全闭塞介入治疗预后获益的现有证据。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-02-29 DOI: 10.3904/kjim.2023.420

David Hong, Sung Eun Kim, Seung Hun Lee, Seung-Jae Lee, Jong-Young Lee, Sang Min Kim, Sang Yeub Lee, Woochan Kwon, Ki Hong Choi, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn, Joo Myung Lee

{"title":"Current evidence for prognostic benefit of intravascular imaging-guided percutaneous coronary intervention in chronic total occlusion intervention.","authors":"David Hong, Sung Eun Kim, Seung Hun Lee, Seung-Jae Lee, Jong-Young Lee, Sang Min Kim, Sang Yeub Lee, Woochan Kwon, Ki Hong Choi, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn, Joo Myung Lee","doi":"10.3904/kjim.2023.420","DOIUrl":"10.3904/kjim.2023.420","url":null,"abstract":"Although percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) has been increasing in recent years, CTO PCI is still one of the most challenging procedures with relatively higher rates of procedural complications and adverse clinical events after PCI. Due to the innate limitations of invasive coronary angiography, intravascular imaging (IVI) has been used as an adjunctive tool to complement PCI, especially in complex coronary artery disease. Considering the complexity of CTO lesions, the role of IVI is particularly important in CTO intervention. IVI has been a useful adjunctive tool in every step of CTO PCI including assisted wire crossing, confirmation of wire location within CTO segment, and stent optimization. The meticulous use of IVI has been one of the greatest contributors to recent progress of CTO PCI. Nevertheless, studies evaluating the role of IVI during CTO PCI are limited. The current review provides a comprehensive overview of the mechanistic advantages of IVI in CTO PCI, summarizes previous studies and trials, and presents future perspective of IVI in CTO PCI.","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"702-716"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer treatment-induced bone loss. 癌症治疗引起的骨质流失。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-03-05 DOI: 10.3904/kjim.2023.386

Yong Jun Choi

引用次数: 0

2024 KSoLA consensus on secondary dyslipidemia. 2024 KSoLA 关于继发性血脂异常的共识。

IF 2.2 4区医学

Korean Journal of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.3904/kjim.2024.156

Hoyoun Won, Jae Hyun Bae, Hyunjung Lim, Minji Kang, Minjoo Kim, Sang-Hak Lee

引用次数: 0